Spinal Muscular Atrophy Treatment Market (By Type: Type1, Type 2; By Treatment: Gene Therapy, Drug; By Drug: Spinraza, Zolgensma; By Route Of Administration) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2023-2032

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Spinal Muscular Atrophy Treatment Market 

5.1. COVID-19 Landscape: Spinal Muscular Atrophy Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Spinal Muscular Atrophy Treatment Market, By Type

8.1. Spinal Muscular Atrophy Treatment Market, by Type, 2023-2032

8.1.1. Type 1

8.1.1.1. Market Revenue and Forecast (2019-2032)

8.1.2. Type 2

8.1.2.1. Market Revenue and Forecast (2019-2032)

8.1.3. Type 3

8.1.3.1. Market Revenue and Forecast (2019-2032)

8.1.4. Type 4

8.1.4.1. Market Revenue and Forecast (2019-2032)

Chapter 9. Global Spinal Muscular Atrophy Treatment Market, By Treatment

9.1. Spinal Muscular Atrophy Treatment Market, by Treatment, 2023-2032

9.1.1. Gene Therapy

9.1.1.1. Market Revenue and Forecast (2019-2032)

9.1.2. Drug

9.1.2.1. Market Revenue and Forecast (2019-2032)

Chapter 10. Global Spinal Muscular Atrophy Treatment Market, By Drug 

10.1. Spinal Muscular Atrophy Treatment Market, by Drug, 2023-2032

10.1.1. Spinraza

10.1.1.1. Market Revenue and Forecast (2019-2032)

10.1.2. Zolgensma (AVXS-101)

10.1.2.1. Market Revenue and Forecast (2019-2032)

10.1.3. Evrysdi

10.1.3.1. Market Revenue and Forecast (2019-2032)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2019-2032)

Chapter 11. Global Spinal Muscular Atrophy Treatment Market, By Route of Administration 

11.1. Spinal Muscular Atrophy Treatment Market, by Route of Administration, 2023-2032

11.1.1. Oral

11.1.1.1. Market Revenue and Forecast (2019-2032)

11.1.2. Injection

11.1.2.1. Market Revenue and Forecast (2019-2032)

Chapter 12. Global Spinal Muscular Atrophy Treatment Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Type (2019-2032)

12.1.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.1.3. Market Revenue and Forecast, by Drug (2019-2032)

12.1.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Type (2019-2032)

12.1.5.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.1.5.3. Market Revenue and Forecast, by Drug (2019-2032)

12.1.5.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Type (2019-2032)

12.1.6.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.1.6.3. Market Revenue and Forecast, by Drug (2019-2032)

12.1.6.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.2. Europe

12.2.1. Market Revenue and Forecast, by Type (2019-2032)

12.2.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.2.3. Market Revenue and Forecast, by Drug (2019-2032)

12.2.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Type (2019-2032)

12.2.5.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.2.5.3. Market Revenue and Forecast, by Drug (2019-2032)

12.2.5.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Type (2019-2032)

12.2.6.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.2.6.3. Market Revenue and Forecast, by Drug (2019-2032)

12.2.6.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Type (2019-2032)

12.2.7.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.2.7.3. Market Revenue and Forecast, by Drug (2019-2032)

12.2.7.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Type (2019-2032)

12.2.8.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.2.8.3. Market Revenue and Forecast, by Drug (2019-2032)

12.2.8.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.3. APAC

12.3.1. Market Revenue and Forecast, by Type (2019-2032)

12.3.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.3.3. Market Revenue and Forecast, by Drug (2019-2032)

12.3.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Type (2019-2032)

12.3.5.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.3.5.3. Market Revenue and Forecast, by Drug (2019-2032)

12.3.5.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Type (2019-2032)

12.3.6.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.3.6.3. Market Revenue and Forecast, by Drug (2019-2032)

12.3.6.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Type (2019-2032)

12.3.7.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.3.7.3. Market Revenue and Forecast, by Drug (2019-2032)

12.3.7.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Type (2019-2032)

12.3.8.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.3.8.3. Market Revenue and Forecast, by Drug (2019-2032)

12.3.8.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.4. MEA

12.4.1. Market Revenue and Forecast, by Type (2019-2032)

12.4.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.4.3. Market Revenue and Forecast, by Drug (2019-2032)

12.4.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Type (2019-2032)

12.4.5.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.4.5.3. Market Revenue and Forecast, by Drug (2019-2032)

12.4.5.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Type (2019-2032)

12.4.6.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.4.6.3. Market Revenue and Forecast, by Drug (2019-2032)

12.4.6.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Type (2019-2032)

12.4.7.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.4.7.3. Market Revenue and Forecast, by Drug (2019-2032)

12.4.7.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Type (2019-2032)

12.4.8.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.4.8.3. Market Revenue and Forecast, by Drug (2019-2032)

12.4.8.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Type (2019-2032)

12.5.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.5.3. Market Revenue and Forecast, by Drug (2019-2032)

12.5.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Type (2019-2032)

12.5.5.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.5.5.3. Market Revenue and Forecast, by Drug (2019-2032)

12.5.5.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Type (2019-2032)

12.5.6.2. Market Revenue and Forecast, by Treatment (2019-2032)

12.5.6.3. Market Revenue and Forecast, by Drug (2019-2032)

12.5.6.4. Market Revenue and Forecast, by Route of Administration (2019-2032)

Chapter 13. Company Profiles

13.1. Biogen

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Novartis AG

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Ionis Pharmaceuticals Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Biohaven Pharmaceuticals

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. F. Hoffmann-La Roche Ltd

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Cytokinetics

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Scholar Rock, Inc.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. PTC Therapeutics

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. NMD Pharma A/S

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms